Taysha Gene Therapies, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Taysha Gene Therapies, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2020 to Q3 2024.
  • Taysha Gene Therapies, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $3.36M, a 64.6% increase year-over-year.
  • Taysha Gene Therapies, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $11.9M, a 18.1% increase year-over-year.
  • Taysha Gene Therapies, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7.91M, a 56.2% decline from 2022.
  • Taysha Gene Therapies, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18M, a 0.78% decline from 2021.
  • Taysha Gene Therapies, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $18.2M, a 442% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $11.9M $3.36M +$1.32M +64.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $10.5M $3.33M +$1.11M +50% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $9.43M $3.2M +$1.52M +90.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $7.91M $1.97M -$2.14M -52% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-19
Q3 2023 $10M $2.04M -$2.43M -54.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $12.5M $2.22M -$1.92M -46.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $14.4M $1.68M -$3.65M -68.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $18M $4.1M -$852K -17.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $18.9M $4.47M -$616K -12.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $19.5M $4.14M -$408K -8.97% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $19.9M $5.33M +$1.74M +48.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $18.2M $4.96M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 $5.09M +$3.75M +279% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $4.55M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $3.59M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q3 2020 $1.34M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.